Liver Recipient Explant Pathology Form

Liver Recipient Explant Pathology Record Field Descriptions

The Liver Recipient Explant Pathology records are generated and available immediately after a transplant event is reported in Waitlist^SM. The liver explant record is completed by the transplant center performing the transplant.

The liver explant record must be completed within 60 days from the record generation date. See OPTN Policy for additional information. Use the search feature to locate specific policy information on Data Submission Requirements.

Provider Information

Recipient Center: The transplant center reported in Waitlist displays. Verify that the center information is the hospital where the transplant operation was performed. The Provider Number is the 6-character Medicare identification number of the hospital. This is followed by the Center Code and Center Name. If the information is incorrect, contact the Help Desk at (800) 978-4334.

Recipient Information

Recipient Name: The name reported in Waitlist displays. Verify the last name, first name and middle initial of the transplant recipient is correct. If the information is incorrect, corrections may be made on the recipient's Transplant Recipient Registration (TRR) record.

DOB: The date of birth reported in Waitlist displays. Verify the date is the recipient's date of birth. If the information is incorrect, corrections may be made on the recipient's TRR record.

Transplant Date: The date of the transplant reported in Waitlist displays.

Note: The transplant date is the date of the beginning of the first anastomosis. If the operation started in the evening and the first anastomosis began early the next morning, the transplant date is the date that the first anastomosis began. The transplant is considered complete when the cavity is closed and the final skin stitch/staple is applied. The transplant date is indicated immediately after a transplant event is reported through the recipient feedback process in Waitlist and in the case of a living donor transplant, where a recipient was added through the donor feedback process in TIEDI^®.

Gender: The gender reported in Waitlist displays. Verify the recipient's gender is correct. If the information is incorrect, corrections may be made on the recipient's TRR record.

SSN: The SSN reported in Waitlist displays. Verify the recipient's Social Security number is correct. If the information is incorrect, contact the Help Desk at 1-800-978-4334.

Clinical Information

Was evidence of HCC (viable or non-viable tumor) found in the explant? If there was any evidence of hepatocellular carcinoma (HCC), click yes and complete the following questions. If there is not any evidence, click No and answer the Pre-transplant treatment for HCC question only. This field is required.

Note: If No is clicked, a message displays containing the following information: If the candidate's explant pathology report does not show evidence of HCC, the transplant center must submit documentation and/or imaging studies used to support the HCC diagnosis at the time of listing.  You may submit documentation by fax to (804) 782-4680, Attention: RRB Admin Supervisor, or by e-mail to LiverPolicy@unos.org.

Number of Tumors: If Yes was selected for was evidence of HCC (viable or non-viable tumor) found in the explant, in the Number of Tumors list, click the appropriate option.

Options: 1, 2, 3, 4, 5, >5, Infiltrative (a large HCC lesion without distinct margins diffusely involving the liver parenchyma)

Note: If the Number of Tumors is > 5, you are required to enter tumor size, location or tumor necrosis for the 5 largest tumors.

Note: If the Number of Tumors is Infiltrative, you are not required to enter tumor size, location or tumor necrosis.

Tumor: For each tumor, complete the following fields.

Size: Enter the size of the tumor in centimeters (cm). If Number of Tumors is 1 or more, this field is required. The largest dimension of each tumor must be reported (e.g., 3.2 cm x 5.1 cm must be reported as 5.1 cm).

Range: 0.01 to 99.99

Location: In the Location list, click the appropriate option. If Number of Tumors is 1 or more, this field is required.

Options: Right Lobe, Left Lobe

Tumor Necrosis: In the Tumor Necrosis list, click the appropriate option. If Number of Tumors is 1 or more, this field is required.

Options: None, Incomplete (any amount of viable tumor remains), Complete (no viable tumor remains)

Worst Tumor Differentiation: If Yes was selected for was evidence of HCC (viable or non-viable tumor) found in the explant, in the Worst Tumor Differentiation list, click the appropriate option. If Number of Tumors is 1 or more, this field is required.

Options: Well, Moderate, Poor, Complete Tumor Necrosis

Vascular Invasion: If Yes was selected for was evidence of HCC (viable or non-viable tumor) found in the explant, in the Vascular Invasion list, click the appropriate option. If Number of Tumors is 1 or more, this field is required. This does not include bland thrombus.

Options: None, Microvascular (vascular invasion seen only under microscopic inspection, synonymous with angiolymphatic or lymphovascular invasion), Macrovascular (any involvement of large vessels noted on gross pathological inspection)

Lymph Node Involvement: If Yes was selected for Was evidence of HCC (viable or non-viable tumor) found in the explant, in the Lymph Node Involvement list, click the appropriate option. If Number of Tumors is 1 or more, this field is required.

Options: Yes, No

Other Extrahepatic Spread: If Yes was selected for Was evidence of HCC (viable or non-viable tumor) found in the explant, in the Other Extrahepatic Spread list, click the appropriate option. If Number of Tumors is 1 or more, this field is required. This is separate from nodal involvement.

Options: Yes, No

Satellite Lesions: If Yes was selected for Was evidence of HCC (viable or non-viable tumor) found in the explant, in the Satellite Lesions list, click the appropriate option. If Number of Tumors is 1 or more, this field is required. Satellite lesions are defined as a tumor nodule which is < 4 cm in diameter, < 2 cm in proximity from the primary tumor, and < 50% of the primary tumor’s diameter.

Options: Yes, No

Pre-transplant treatment for HCC?: If the recipient received any pre-transplant treatment for HCC, click Yes. If the recipient did not receive any pre-transplant treatment for HCC, click No. This field is required.  Examples of loco-regional therapy include TACE (trans-arterial chemoembolization) RFA (radiofrequency ablation), and radiolabeled microsphere treatment.